

TheraVab Biosciences Announces Exclusive Option to License Engineered Receptor Immunobiotherapy for the Treatment of Neu



Singapore, Sep 28, 2020 ([Issuewire.com](https://www.issuewire.com)) - TheraVab Biomedics Pte. Ltd. (a subsidiary of TheraVab Biosciences Pte. Ltd., Singapore) announced today that it has entered into an agreement with the University of Florida Research Foundation (Gainesville, FL USA) for the exclusive option to license decoy receptor technology for the development of an immunotherapy targeting neuroinflammatory diseases including Parkinson's (PD) and Alzheimer's (AD) diseases. In the United States, as of 2019, incidence of AD and PD is at a record high with 5.5 million cases of AD and 930,000 cases of PD, with numbers only projected to increase in 2020.

"The use of engineered decoy receptors to therapeutically target misfolded protein aggregates may offer an important treatment option for neuroinflammatory diseases including AD and PD," said Herbert Chow, Ph.D., CEO/CSO of TheraVab Biosciences. "TheraVab is committed to identifying promising biotherapeutic candidates such as the decoy receptor platform that may be synergistic with our recombinant antigen-specific antibodies that targets different misfolded protein aggregates."

Jim O'Connell, assistant vice president of UF Innovate, the technology commercialization arm of the University of Florida, commented, "It is very gratifying to our research group that TheraVab is taking the lead in commercializing our engineered receptor technology and to see that our scientific discoveries may soon be available to the public and provide a significant positive impact on global health."

The global number of people living with neurodegenerative diseases more than doubled from 1990 to 2019, mainly due to increases in population aging and growth. Until breakthroughs are made in prevention or curative treatment, dementia will constitute an increasing challenge to health-care systems worldwide. By directly interacting with misfolded protein aggregate levels in vivo, the engineered decoy receptor represents a novel class of immunomodulatory agents for neuroinflammatory diseases.

For more about neuroinflammatory diseases, visit:

[Forecasting](#) the global burden of Alzheimer's disease Brookmeyer et al. Alzheimer's Dement 2007 Jul;3(3):186-91

The burden of Parkinson's disease: a worldwide perspective Rocca The Lancet 2018 Vol 17(11):928-929

About the University of Florida, FL USA

Hera Lichtenbeld

Assistant Director, Life Sciences

UF Innovate

h.lichtenbeld@ufl.edu

<https://innovate.research.ufl.edu/tech-licensing/>

University of Florida Innovate is building business on innovation. It is the umbrella organization uniting the five entities that drive the innovation ecosystem at UF. Based at one of the nation's leading research institutions, UF Innovate comprises Tech Licensing, Ventures, Corporate Engagement, and two business incubators, The Hub and Sid Martin Biotech. Together, those organizations move research discoveries from the laboratory to the market. UF Innovate connects innovators with entrepreneurs, investors, and industry, incubates startups and growth companies, and fosters a resilient economy — all in an effort to make the world a better place.

About TheraVab Biosciences Pte. Ltd. Singapore

Herbert Chow, Ph.D.

CEO/CSO

herb@theravab.io

<https://www.theravab.io/>

TheraVab is a Singapore biopharmaceutical company focused on developing or acquiring technologies that help develop immunobiotherapies. Our model is based on early-stage biologic research and pre-

clinical development. We generate our revenue by partnering with other pharmaceutical companies to move early stage biologics into regulatory phase and commercialization. Our product candidates and products emphasize particularly on disease segments with huge unmet needs in the global market. These include neurodegenerative disorders, inflammatory diseases, and cancers. At TheraVab, we make use of proprietary algorithms for designing, screening and choosing novel human monoclonal antibodies, antibody fragments and decoy receptors with particular affinity to various therapeutic targets and diseases molecules. Along with building stronger internal teams and processes that leveraged on a propriety blockchain platform through partnership with dClinic (Singapore) and Deloitte Touche Tohmatsu Limited (DTTL Singapore), our focus continues to be significant health improvements at a global scale. We aim to build a robust biotherapy pipeline that enhances recovery and improves lives of those suffering from severe inflammatory ailments, and cancers. We believe in harnessing the power of scientific research and cutting-edge technology towards a brighter and better future for humankind.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein.

Media Contact

TheraVab Biosciences Pte Ltd.

herb@theravab.io

4 Battery Road, Bank of China Building #25-01, Singapore 049908

Source : University of Florida, UF Innovate

[See on IssueWire](#)